Welcome to gastrointestinal oncology Friday, where we highlight notable pieces of content featured on GI Oncology Now. This week, we shed light on important data relevant to liver, colorectal, and pancreatic cancer.
Histotripsy, an emerging, noninvasive technology for performing tumor removal, offers several advantages for treating liver tumors, including real-time ultrasound feedback.
A study of real-world data assessed whether the addition of an anti-VEGF agent to the first-line treatment regimen of leucovorin calcium folinic acid, fluorouracil, and oxaliplatin impacted outcomes in patients with metastatic colorectal carcinoma.
GEP-NETs are usually slow-growing tumors; however, some patients experience rapid progression, and all advanced diseases become treatment resistant. Researchers evaluated how grade progression and intertumoral or intratumoral heterogeneity may be related to these features of patients with GEP-NETs.
Nimotuzumab plus gemcitabine demonstrated a favorable safety profile and significantly improved survival in patients with locally advanced or metastatic pancreatic cancer.
Wishing a safe and happy weekend to all of our readers. Until next time!
But before you go, check out more GI Oncology Now news.